Immuno-polymeric drugs for prostate cancer therapy

用于前列腺癌治疗的免疫聚合物药物

• 批准号: nhmrc : 1099321
• 负责人: A/Pr Kristofer Thurecht
• 金额: $ 43万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/immuno-polymeric-drugs-cancer-therapy/662442
• 关键词: Immuno; polymeric; drugs; prostate; cancer

Prostate cancer is the most common cancer in men over 50 and the second most frequent cause of cancer deaths in Western society. Docetaxel is the first line of chemotherapy when other intervention strategies are unsuccessful, but 30% of patients suffer from severe side-effects. To address this problem, we will utilise carriers for docetaxel that directly target prostate tumours using a novel antibody approach. This increases accumulation at the tumour site while decreasing off-target toxicity.

前列腺癌是50岁以上男性最常见的癌症，也是西方社会第二常见的癌症死亡原因。当其他干预策略不成功时，多西紫杉醇是一线化疗药物，但30%的患者遭受严重副作用。为了解决这个问题，我们将利用多西紫杉醇的载体，通过一种新的抗体方法直接靶向前列腺癌。这增加了肿瘤部位的蓄积，同时减少了靶外毒性。